Remove 2023 Remove Clinical Development Remove Drug Development Remove Research
article thumbnail

2023 cancer research highlights: Drug development at its best

Drug Discovery World

Lu Rahman selects some of the year’s interesting and noteworthy advances in cancer research drug discovery and development. As always, a year within cancer drug discovery and development brings with it significant breakthroughs, and 2023 has been no exception. Research into new cancer drugs remain strong.

article thumbnail

The DDW Podcast: 2023 in review

Drug Discovery World

As 2023 draws to a close, DDW’s Multimedia Editor and podcast host Megan Thomas rounds up all the free episodes of the DDW podcast that were released. You can also find The Drug Discovery World Podcast on Spotify , Google Play and Apple Podcasts. Developing. DDW Highlights Innovative. Listen here. Listen here. Listen here.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

#ScienceSaturday: September 30, 2023

KIF1A

#ScienceSaturday posts share exciting scientific developments and educational resources with the KAND community. Each week, Dr. Dylan Verden of KIF1A.ORG summarizes newly published KIF1A-related research and highlights progress in rare disease research and therapeutic development. What’s a pre-print?

FDA 111
article thumbnail

Bayer and Broad Institute extend cancer therapy research collaboration

Broad Institute

Bayer and Broad Institute extend cancer therapy research collaboration By Corie Lok November 2, 2023 Breadcrumb Home Bayer and Broad Institute extend cancer therapy research collaboration Long-standing industry-academia collaboration has already resulted in three clinical oncology candidates.

Therapies 105
article thumbnail

The Power of Personalization Amid the Changing CRO Landscape

Conversations in Drug Development Trends

Amidst a shifting clinical landscape characterized by increasingly complex trial designs and growing patient subpopulations, many contract research organizations (CROs) have adopted a “one-stop-shop” strategic approach. What Differentiates Mid-Size CROs?

article thumbnail

On the Road at ASCO 2023: Key Takeaways, Observations and Reflections

LifeSciVC

Redig, SVP and Head of Clinical Development at HotSpot Therapeutics, as part of the From The Trenches feature of LifeSciVC The American Cancer Society for Oncology (ASCO) annual meeting is among the highlights of the clinical oncology calendar. By Amanda J. We owe it to our patients to step firmly on the scientific accelerator.”

article thumbnail

International Women’s Day: Female life science leaders

Drug Discovery World

Powers taught for more than six years at the National Institutes of Health, on medical product development and commercialisation, and at Georgetown Law School as an adjunct professor. Dr Janette Thomas, CEO, Five Alarm Bio Five Alarm Bio is an anti-ageing therapeutics company, which completed a seed investment round in early 2023.